Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avecho BiotechnologyASX:AVE -2.44% Net Debt Paydown Yield % is 0.72% as of Jul. 14, 2026. The stock has 2 warning signs investors should review. Among 1,160 Biotechnology companies, Avecho Biotechnology ranks better than 70.69% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Avecho Biotechnology's Net Debt Paydown Yield % was 0.72%.
Avecho Biotechnology (ASX:AVE) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Avecho Biotechnology Net Debt Paydown Yield % Related Terms
Avecho Biotechnology Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Avecho Biotechnology's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avecho Biotechnology Net Debt Paydown Yield % Chart
ASX:AVE vs VRTX, REGN, ALNY: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Avecho Biotechnology's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avecho Biotechnology Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Avecho Biotechnology's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.72% mean?
Avecho Biotechnology (ASX:AVE) has a Net Debt Paydown Yield % of 0.72% as of Jul. 14, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Avecho Biotechnology and its competitors. According to the industry distribution chart, Avecho Biotechnology ranks #340 out of 1160 companies in the Biotechnology industry, placing it in the top 29.3%.
Is Avecho Biotechnology's Net Debt Paydown Yield % too high?
Avecho Biotechnology's current Net Debt Paydown Yield % is 0.72%. The Biotechnology industry median Net Debt Paydown Yield % is 0.04. Avecho Biotechnology's value of 0.72% is 1957.1% above this industry median. Based on the distribution chart, Avecho Biotechnology ranks #340 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint.
How does Avecho Biotechnology's Net Debt Paydown Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avecho Biotechnology ranks #340 out of 1160 companies for Net Debt Paydown Yield %. This puts Avecho Biotechnology in the upper half of its industry. The industry median Net Debt Paydown Yield % is 0.04. Avecho Biotechnology's value of 0.72% is 1957.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.04, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avecho Biotechnology's current Net Debt Paydown Yield % of 0.72% is 1957.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Avecho Biotechnology and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avecho Biotechnology's current Net Debt Paydown Yield % is 0.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (ASX:AVE) has a current Net Debt Paydown Yield % of 0.72%. The current Net Debt Paydown Yield % is 0.72% and 1957.1% above the Biotechnology industry median of 0.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Avecho Biotechnology (ASX:AVE), the current Net Debt Paydown Yield % is 0.72% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVE has been successfully added to your 
